

CURRICULUM VITAE

Name: Robert Dean Shamburek, M.D.

Date and Place of Birth: [-----]

Citizenship: [-----]

Marital Status: [-----]

Education:

[--] – B.S. (Biology), Marquette University, Milwaukee, Wisconsin

[--] – M.D., University of Virginia Hospital, Charlottesville, VA

Board Certification:

Certified Diplomat in Internal Medicine by American Board of Internal Medicine, [-----
-----]

Certified Diplomat in Gastroenterology by American Board of Gastroenterology, [-----
-----]

Geriatrics, board eligible

Brief Chronology of Employment:

1984-1987	Internship and Residency, Internal Medicine, Medical College of Virginia, Richmond, Virginia.
1987-1988	Geriatric Fellowship, Medical College of Virginia, Richmond, Virginia.
1988-1991	Clinical Fellowship, Gastroenterology, Medical College of Virginia, Richmond, Virginia.
1989-1991	Trainee, Gastroenterology, Divisional NRSA (NIH), Medical College of Virginia, Richmond, Virginia.
1990-1991	Instructor of Medicine, Medical College of Virginia, Richmond, Virginia.
1991-1992	Trainee, Gastroenterology, Individual NRSA (NIH), Medical College of Virginia, Richmond, Virginia.
1991-1993	Assistant Professor of Medicine, Medical College of Virginia, Richmond, Virginia.
1993-1999	Senior Staff Fellow, Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
1993-Present	Head of Inpatient Lipid Service
1999-2005	Clinician/Scientist, Molecular Disease Branch, National Heart,

2006-Present Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Clinician/Scientist, Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Honors and Other Special Scientific Recognition:

Alpha Epsilon Delta - National Premedical Honor Society [---]
Phi Sigma Award - Biological Sciences Honor Society Award [--]
Phi Beta Kappa [--]
AGA - Glaxo Research, Fellow Award [---]
NIH Fellows Award for Research Excellence 1998
Fellow – American Heart Association [--]
Merck Young Investigator Award [---]

Military:

None

Responsibilities:

1993-Present Head of the Lipid Metabolism Ward, MDB
1993-Present Institute Review Board Member, NHLBI
1997-2000 Physician Representative – 8E Ward Committee for JCAHO
1998-1999 Acting IRB Secretary, NHLBI
1999-2000 IRB Secretary, NHLBI
1998-Present Normal Volunteer Committee, NIH
2003-present GI Consult Service for NIH Clinical Center
2004-Present Animal Care and Use Committee, NHLBI
2005-2006 Vice-chairperson, Animal Care and Use Committee, NHLBI
2006-Present Chairperson, Animal Care and Use Committee, NHLBI
2006-Present Technology Advisory Committee (TEAC) Committee, NHLBI

Invited Reviewer:

4/14/04 AHA Grant Peer Reviewer, Mid-Atlantic Research
4/14/05 AHA Grant Peer Reviewer, Mid-Atlantic Research
11/17/04 Ad Hoc reviewer, NIDDK, Extramural Program Project review
12/5/05 Ad Hoc reviewer, NIDDK, Intramural clinical proposal
7/27/06 Ad Hoc reviewer, NIDDK, Extramural Program Project review

Professional Organizations:

American Federation for Clinical Research
American Gastroenterological Association

American Heart Association

Invited Presentations:

Shamburek RD, Schwartz CC. "HDL Phosphatidylcholine hydrolysis by a phospholipase A₁ and the hepatic uptake of the products." Presented at the Third Mid-Atlantic Lipid Research Symposium in Atlantic City, NJ, May 2, 1991.

Shamburek RD, Pandak WM, Vlahcevic ZR and Schwartz CC. "Inhibition of bile acid synthesis by mevinolin is related to reduction of newly synthesized cholesterol substrates." Presented at the 9th International Symposium on Atherosclerosis in Chicago, IL, October 7, 1991.

Shamburek RD, Schwartz CC. "1-stearoyl-2-arachidonyl-phosphatidylcholine is the preferred substrate for cholesteryl ester formation by LCAT *in vivo*." Presented at the Fifth Mid-Atlantic Lipid Research Symposium in Atlantic City, NJ, May 1993.

Shamburek RD, Schwartz CC. "1-stearoyl-2-arachidonyl-phosphatidylcholine (SAPC) is the preferred substrate for cholesteryl ester formation by LCAT *in vivo*." Kinetic meeting during AHA meeting in New Orleans, LA, November 8-11, 1993.

Shamburek RD, Berard A, Vaisman B, Santamarina-Fojo S, Brewer Jr. HB. "Overexpression of LCAT: *in vivo* metabolism of apoA-I and apoA-II." Presentation at the HDL Satellite Meeting of the Xth International Symposium on Atherosclerosis, Halifax, Canada. October 14-16, 1994.

Shamburek RD, Zech LA, Meyn S, Kindt M, Talley G, Hedrick C, Castellani L, Brewer HB. "ApoA-I and ApoA-II metabolism in transgenic mice overexpressing apoA-II." AHA meeting in Dallas, Texas. November 14-17, 1994.

Shamburek RD, Zech LA, Talley G., Ronan R., Brewer HB. "Apolipoprotein metabolism in mice versus humans." Kinetic meeting during AHA meeting in Anaheim, CA. November 12-16, 1995.

Shamburek RD, Zech LA, Talley G., Ronan R., Hedrick C, Castellani L, Brewer HB. "ApoA-E and ApoA-II metabolism in transgenic mice overexpressing apoA-II." AHA meeting in Anaheim, CA. November 12-16, 1995.

Shamburek RD, Brewer Jr. HB. "Lipoprotein metabolism and atherosclerosis." Presented at A review of endocrinology: Diagnosis and treatment. FAES Endocrinology Board Review in Bethesda, MD. September 9, 1998.

Shamburek RD, Brewer Jr, HB. "High triglycerides and low HDL: Are they risk factors for CAD and what are the therapeutic implications?" Presented at American College of

Cardiology Program - New Techniques and Concepts in Cardiology. Washington D.C. October 22, 1998.

Shamburek RD. Statins in Polymyositis. NIAMS Rheumatology Grand Rounds, NIH. Bethesda, MD. August 18, 2000.

Shamburek RD. Lipid update: back to your ABC's. Medical College of Virginia, Richmond, Va. October 7, 2000.

Shamburek RD, Carusso R. Clinical manifestations of abetalipoproteinemia and hypobetalipoproteinemia. NEI Clinical Conference Grand Rounds, NIH. Bethesda, MD. January 31, 2001.

Shamburek RD, Sarlis NJ, Skarlis M. Multi-organ failure in a patient with severe thyrotoxicosis and pre-existing cardiomyopathy. NIDDK Multi-Specialty Clinical Conference, Bethesda, MD. April 26, 2001.

Shamburek RD, VandenBroek JM, Cooper PS, Brewer Jr. HB, Schwartz CC. Cholesteryl ester output to tissues directly from HDL is minimal in humans. AHA meeting in Orlando, FL. November 9-12, 2003.

Shamburek RD. "Advances in the Pharmacologic Management of Cholesterol Disorders." Pharmacotherapy Frontiers 2004, Pharmacy Dept, NIH. Bethesda, MD. May 15, 2004.

Shamburek RD. Advances in the Management of Cholesterol Disorders From ABC's to ATP III. Suburban Hospital Grand Rounds. Suburban Hospital, Bethesda, MD. January 28, 2005.

Shamburek RD. Skin manifestations of abetalipoproteinemia. Dermatology Grand Rounds, NIH. Bethesda, MD. May 26, 2005.

Shamburek RD. "Lipids and hyperlipidemia." Presented at A Review of Endocrinology: Diagnosis and Treatment. FAES Endocrinology Board Review in Bethesda, MD. October 19, 2005.

BIBLIOGRAPHY

- 1 Schubert ML, Shamburek RD: Control of acid secretion. *Gastroenterol Clin North Am* 19:1-25, 1990.
- 2 Shamburek RD, Farrar JT. Disorders of the digestive system in the elderly. *N Engl J Med* 322:438-442, 1990.
- 3 Shamburek RD, Scott RB, Farrar JT. Gastrointestinal and liver changes in the elderly. MR Katlic (ed). In: *Surgical Management of the Elderly Patient*. Urban & Schwarzenberg, Inc., Baltimore, MD. pp. 97-113. 1990.
- 4 Shamburek RD, Schubert ML. Control of acid secretion. Histamine H₂-receptor antagonists and H⁺K⁺-ATPase inhibitors. *Gastroenterol Clin North Am* 21:527-50, 1992.
- 5 Shamburek RD, Ruddy S, Schubert ML. Omeprazole and neutrophil function. *Gastroenterology* 104:938-40, 1993.
- 6 Shamburek RD, Schubert ML. Pharmacology of gastric acid secretion. *Baillieres Clin Gastroenterol* 7:23-54. 1993.
- 7 Shiffman ML, Shamburek RD, Schwartz CC, Sugerman HJ, Kellum JM, Moore EW. Gallbladder mucin, arachidonate acid, and bile lipids in patients who develop gallstones during weight reduction. *Gastroenterology* 105:1200-9, 1993.
- 8 Shamburek RD, Pandak WM, Schwartz CC. Identification, nutritional management, and drug therapy of patients with lipid disorders. *Prac Gastroenterology* 18:25-35, 1993.
- 9 Shamburek RD, Schwartz CC. Selective composition of biliary phosphatidylcholines is affected by secretion rate but not by bile acid hydrophobicity. *J Lipid Res* 34:1833-42, 1993.
- 10 Barr WH, Zola EM, Candler EL, Hwang S, Tendolkar AV, Shamburek R, Parker B, Hilty MD. Differential absorption of amoxicillin from the human small and large intestine. *Clin Pharmacol Ther* 56:279-85, 1994.
- 11 Hsyu PH, Pritchard JF, Bozigian HP, Lloyd TL, Griffin RH, Shamburek RD, Krishna G, Barr WH. Comparison of the pharmacokinetics of ondansetron solution (8mg) when administered intravenously, orally, to the colon, and the rectum. *Pharm Res* 11:156-9, 1994.
- 12 Shamburek RD, Schubert ML. Structure and function of the stomach: role of the

- proton pump. RH Hunt (ed). In: *Proton pump inhibitors and acid-related disorders*. Adis International Ltd, Osaka, pp. 11-28, 1994.
- 13 Boyd JW, DeLegge MH, Shamburek RD, Kirby DF. The buried bumper syndrome: a new technique for safe, endoscopic PEG removal. *Gastroint Endo* 41:508-511, 1995.
 - 14 Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, Meyn S, Parrott C, Maeda N, Shamburek R, Brewer HB, Jr. Hepatic lipase gene therapy in hepatic lipase-deficient mice. *J Clin Invest* 97:799-805, 1996.
 - 15 Brown DR, Brousseau ME, Shamburek RD, Talley GD, Meyn S, Demonsky SJ, Santamarina-Fojo S, Brewer Jr. HB, Hoeg JM. Adenoviral delivery of low density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins. *Metabolism* 45:1447-1457, 1996.
 - 16 Shamburek RD, Zech LA, Cooper PS, VandenBroek JM, Schwartz CC. Disappearance of two major phosphatidylcholines from plasma is predominantly via LCAT and hepatic lipase. *Am J Physiol* 271:E1073-82, 1996.
 - 17 Berard AM, Foger B, Remaley A, Shamburek R, Vaisman B, Talley G, Paigen B, Marcovina S, Brewer Jr. HB, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesterol acyltransferase. *Nature Medicine* 3:744-749, 1997.
 - 18 Schmidt HH, Gregg RE, Shamburek R, Brewer Jr. HB, Zech LA. Erdheim-Chester Disease: Low-density lipoprotein levels due to rapid catabolism. *Metabolism* 46:1215-1219, 1997.
 - 19 Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer Jr HB. Plasma phospholipid transfer protein: Adenovirus mediated overexpression in mice leads to decreased plasma HDL and enhanced hepatic uptake of phospholipids and cholesterol esters from HDL. *J Biol Chem* 272:27393-27400, 1997.
 - 20 Shamburek RD, Pentchev PG, Zech LA, Blanchette-Mackie J, Carstea ED, VandenBroek JM, Cooper PS, Neufeld EB, Phair RD, Brewer Jr HB, Brady RO, Schwartz CC. Intracellular trafficking of free cholesterol derived from LDL cholesterol ester is defective *in vivo* in Niemann-Pick C disease: Insights on normal metabolism of HDL and LDL gained from the NP-C mutation. *J Lipid Res* 38:2422-2435, 1997.
 - 21 Schmidt HHJ, Stuhmann M, Shamburek R, Schewe CK, Ebhardt M, Zech LA, Buttner C, Wendt M, Beisiegel U, Brewer, Jr. HB, Manns MP. Delayed low density lipoprotein (LDL) catabolism despite a functional intact LDL-apolipoprotein B particle

- and LDL-receptor in a subject with clinical homozygous familial hypercholesterolemia. *J Clin Endo Met* 83:2167-2174, 1998.
- 22 Amar MJA, Dugi KA, Haudenschild CC, Shamburek RD, Foger B, Chase M, Bensadoun A, Hoyt, Jr. RF, Brewer Jr. HB, Santamarina-Fojo S. Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoE-deficient mice. *J Lipid Res* 39:2436-2442, 1998.
- 23 Foeger B, Chase M, Amar JA, Vaisman BL, Shamburek RD, Paigen G, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt Jr RF, Brewer Jr HB, Santamarina-Fojo S. Cholesterol ester transfer protein corrects dysfunctional HDL and reduces aortic atherosclerosis in lecithin:cholesterol acyltransferase (LCAT)-transgenic mice. *J Biol Chem* 274:36912-36920, 1999.
- 24 Dugi KA, Amar MJA, Haudenschild CC, Shamburek RD, Bensadoun A, Hoyt Jr RF, Fruchart-Najib J, Madj J, Brewer Jr HB, Santamarina-Fojo S. *In vivo* evidence for both lipolytic and nonlipolytic functions of hepatic lipase in the metabolism of high density lipoproteins. *ATVB* 20:793-800, 2000.
- 25 Lambert G, Amar MJA, Martin P, Fruchart-Najib J, Foger B, Shamburek RD, Brewer Jr HB, Santamarina-Fojo S. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters *in vivo*. *J Lipid Res* 41:667-672, 2000.
- 26 Shamburek RD, Brewer Jr HB, Gochuico BR. Erdheim-Chester disease: A rare multisystem histiocytic disorder associated with interstitial lung disease. *Amer J Med Sci* 321:66-75, 2001.
- 27 Summers RM, Choyke PL, Patronas NJ, Tucker E, Wise B, Busse MK, Brewer Jr HB, Shamburek RD. Magnetic resonance angiography of thoracic aortic atherosclerosis in homozygous familial hypercholesterolemia. *J Comput Assist Tomo* 25:371-377, 2001.
- 28 Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer HB, Santamarina-Fojo S. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. *J Clin Invest* 108:303-309, 2001.
- 29 Hannuksela ML, Brousseau ME, Meyn SM, Nazih H, Bader G, Shamburek RD, Alaupovic P, Brewer Jr. HB. *In vivo* metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-1, LpE:A-II and LpE:A-I:A-II. *Atherosclerosis* 165:205-220, 2002.
- 30 Shamburek RD. Erdheim-Chester Disease. E. Gruson (ed). In: *The NORD Guide to Rare Disorders*. Lippincott, Williams & Wilkins. Philadelphia, PA.

p 441, 2003.

- 31 Uwaifo GI, Summer A, Shamburek R, Sarlis NJ,. A case of familial dysbetalipoproteinemia with very low serum high-density lipoprotein-cholesterol: response to atorvastatin therapy. *The Endocrinologist* 13:85-90, 2003.
- 32 Wu JE, Basso F, Shamburek RD, Amar MJ, Vaisman B, Szakacs G, Joyce C, Tansey T, Freeman L, Paigen BJ, Thomas F, Brewer Jr HB, Santamarina-Fojo S. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice' *J. Biol. Chem* 279:22913-22925, 2004.
- 33 Gonzalez-Navarro H, Nong Z, Amar MJ, Shamburek RD, Paigen BJ, Brewer Jr HB, Santamarina-Fojo S. The ligand-binding function of HL modulates the development of atherosclerosis in transgenic mice. *J Biol Chem* 279:45312-21, 2004.
- 34 Ikewaki K, Cain W, Thomas F, Shamburek R, Zech LA, Usher D, Brewer Jr HB, Rader DJ. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency. *J Lipid Res* 45:1302-11, 2004.
- 35 Brewer Jr HB, Santamarina-Fojo S, Shamburek RD. Genetic Dysliporproteinemia. V Fuster, EJ Topol, and EG Nabel (eds). In: *Atherothrombosis and Coronary Artery Disease*. Lippincott Williams & Wilkins, Philadelphia, PA. pp. 55-84. 2005.
- 36 Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. *Pharmacotherapy* 25:171-183, 2005.
37. Gonzalez-Navarro H, Amar MJA, Freeman L, Shamburek R, Paigen B, Brewer HB Jr, Santamarina-Fojo S. Lipolytic and Ligand-Binding Functions of Hepatic Lipase Protect Against Atherosclerosis in LDL Receptor-Deficient Mice. *Arterioscler Thromb. Vasc. Biol.*, submitted. 2005.
38. [-----]
-----]
-----] In press.
39. [-----]
-----] (Submitted)
- 40 [-----]
(Submitted)

ABSTRACTS

- 1 Shamburek RD, Scagnelli GP, Cooper PS, Schwartz CC. Taurocholic acid regulates plasma phosphatidylcholine (PC) catabolism by hepatic phospholipase A1. *Gastroenterology* 98:A631, 1990.
- 2 Shamburek RD, Pandak WM, Vlahcevic ZR, Schwartz CC. Inhibition of bile acid synthesis by mevinolin is related to reduction of newly synthesized cholesterol substrate. *Gastroenterology* 100:A794, 1991.
- 3 Shamburek RD, Shiffman ML, Moore EW, Schwartz CC. Molecular species of phosphatidylcholine (PC) in gallbladder bile of obese patients before and after gallstone formation. *Gastroenterology* 100:A794, 1991.
- 4 Purdum PP, Shamburek RD, Hylemon PB, Moore EW. Rapid phospholipid transfer across cultured human gallbladder epithelia. *Gastroenterology* 102:A871, 1992.
- 5 Shamburek RD, Nishiwaki M, Ishikawa T, Nakamura H, Ikewaki K, Zech LA, Rader HB, Brewer HB, Schwartz CC. Cholesteryl ester transfer protein Deficiency: *in vivo* metabolism of free and esterified cholesterol. *Circulation* 88:175. 1993.
- 6 Shamburek RD, Hanson-Bundy SL, Schwartz CC. Cholinephosphotransferase (CPT) is directly involved in bile phospholipid secretion: evidence based on substrate specificity. *Gastroenterology* 106:A981, 1994.
- 7 Brown DR, Hoeg JM, Shamburek RD, Brousseau ME, Talley GD, Meyn S, Santamarina-Fojo S, Brewer Jr. HB. Adenoviral delivery of low density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high density lipoprotein metabolism. *Cold Springs Harbor*, 1994.
- 8 Shamburek RD, Zech LA, Meyn S, Kindt M, Talley G, Hedrick C, Castellani L, Brewer Jr HB. ApoA-I and ApoA-II metabolism in transgenic mice overexpressing apoA-II. *Circulation* 90:1-81. 1994.
- 9 Berard A., Shamburek RD, Vaisman B, Meyn S, Kindt M, Albers J, Santamarina-Fojo S, Brewer Jr HB. Differential dietary response of mice overexpressing hLCAT. *Circulation* 90:1-82. 1994.
- 10 Brown DR, Hoeg JM, Shamburek RD, Brousseau ME, Talley GD, Santamarina-Fojo S, Brewer Jr HB. Adenoviral delivery of LDL receptors raises plasma apolipoprotein A-I concentrations by delaying apolipoprotein A-I catabolism. *Circulation* 90:1-240. 1994.
- 11 Shamburek RD, Zech LA, G Talley, R. Ronan, Hedrick C, Castellani L, Brewer HB. ApoA-E and ApoA-II metabolism in transgenic mice overexpressing apoA-II. *Circulation* 92:1-105. 1995.

- 12 Phair RD, Shamburek RD, Brewer Jr. HB, Schwartz CC. Direct determination of *in vivo* cholesteryl ester transfer from HDL to LpB subclasses. In: *Gordon Conference on Lipid Metabolism*, Meridan, NH. June 1996.
- 13 Bader G, Edelstein C, Shamburek RD, Nishiwaki M, Nazih H, Schwartz C, Scanu AM, Brewer Jr. HB. Lp(a): Comparison of the *in vivo* metabolism of apo(a) and Lp(a) in man. *Circulation* 94:1-39. 1996.
- 14 Nishiwaki M, Bader G, Nazih H, Shamburek RD, Schwartz C, Talley GD, Brewer Jr. HB. Lecithin Cholesterol Acyl Transferase: Human *in vivo* kinetics of LDL and LpX-like lipoproteins. *Circulation* 94:1-275. 1996.
- 15 Foger B, Santamarina-Fojo S, Shamburek RD, Parrott CL, Tallet G, Brewer Jr. HB. Phospholipid transfer protein: adenovirus mediated overexpression in mice leads to decreased plasma HDL, increased VLDL-LDL and accelerated hepatic uptake of phospholipids. *Circulation* 94:1-276. 1996.
- 16 Amar MJA, Shamburek RD, Maeda N, Kindt MR, Santamarina-Fojo S, Brewer Jr. HB. Adenovirus mediated expression of hepatic lipase in apoE deficient mice: evidence for hepatic lipase-mediated clearance of remnant lipoprotein. *Circulation* 94:1-398. 1996.
- 17 Shamburek RD, Ikewaki K, Zech LA, Brewer Jr. HB. Apolipoprotein J: human *in vivo* metabolism of LpJ and LpJ:A-I. *Circulation* 94:1-583. 1996.
- 18 Hannuksela ML, Meyn SM, Talley GD, Nazih H, Bader G, Shamburek RD, Alaupovic P, Brewer Jr. HB. The *in vivo* metabolism of apolipoprotein E-containing high density lipoproteins. *Circulation* 96:1-723. 1997.
- 19 Shamburek RD, Talley GD, Kindt MR, Kuivenhoven JA, Kastelein JJP, Stalenhoef AFH, Brewer Jr, HB. Lecithin-cholesterol acyltransferase deficiency: human *in vivo* kinetics of LDL, apoA-I and apoA-II in partial LCAT deficiency (fish eye disease) with and without CAD. *Circulation* 96:1-723. 1997.
- 20 Bader B, Edelstein C, Shamburek RD, Brewer Jr, HB. The *in vivo* metabolism of free Apo(a) in normals and subjects with abetalipoproteinemia. *Atherosclerosis* 134:137. 1997.
- 21 Nishiwaki M, Ishikawa T, Nazih H, Bader G, Remaley A, Tally G, Shamburek R, Hannuskela M, Brewer Jr. HB. Human lecithin:cholesterol acyltransferase deficiency: *In vivo* LpX kinetics and its cell association with various cells. *Atherosclerosis* 134:352. 1997.

- 22 Chase MB, Santamarina-Fojo S, Shamburek RD, Amar MJ, Knapper CL, Meyn SM, Brewer Jr, HB. CLA-1/SR-B1: *in vivo* evidence for selective uptake of cholesterol esters from apoB remnant lipoproteins in apoE deficient mice. *Circulation* 98:1-202, 1998.
- 23 Shamburek RD, Dinger ML, Talley GD, Kindt MR, Brewer Jr, HB. ApoA-I and apoA-II metabolism in hyperalphalipoproteinemia induced by ETOH. *Circulation* 98:1-239 1998.
- 24 Amar MJ, Shamburek RD, Foger B, Hoyt RF Jr., Wood DO, Santamarina-Fojo S, Brewer HB Jr. Adenovirus-mediated expression of LCAT in non-human primates leads to an antiatherogenic lipoprotein profile with increased HDL and decreased LDL. *Circulation* 98:1-35, 1998.
- 25 Shamburek RD, Hoeg JM, Duverger N, Houbebene LM, Hoyt Jr, RF, Wood DO, Santamarina-Fojo S, Brewer, Jr. HB. Transgenic rabbits expressing both human ApoA-I and LCAT have a protective lipoprotein profile with increased HDL and enhanced LDL catabolism. *Circulation* 100:2112, 1999.
- 26 Chase MB, Amar MJA, Shamburek RD, Lambert GC, Knapper CL, Allen DA, Santamarina-Fojo S, Brewer, Jr. HB. Adenovirus-mediated expression of scavenger receptor Type B Class I (SR-BI) corrects the reverse cholesterol transport defect associated with LCAT transgenic mouse HDL. *Circulation* 100:185, 1999.
- 27 Summers RM, Pusanik LM, Malley JD, Shamburek RD. Fractal analysis of virtual endoscopy reconstruction. SPIE Medical Imaging, San Diego, Ca. Febraury, 1999.
- 28 Lambert G, Amar MJA, Shamburek RD, Hoyt, Jr. RF, Madj Z, Fruchart-Najib J, Brewer, Jr., HB, Santamarina-Fojo S. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters *in vivo*. *Circulation* 100:1322, 1999.
- 29 Sandbrink F, Shamburek RD, Syed NA, Molloy FM, Culcea E, Floeter MK. Cutaneous silent periods in abetalipoproteinemia. *Muscle and Nerve* 9:1324, 1999.
- 30 Ito T, Sabol S, Amar M, Knapper C, Duarte C, Shamburek RD, Meyn S, Santamarina-Fojo S, Brewer Jr HB. Adenovirus-mediated expression establishes an *in vivo* role for human ABCG1 (ABC8) in lipoprotein metabolism. *Circulation* 102:1525, 2000.
- 31 Shamburek RD, Nong Z, Fyfe JC, Hoyt Jr R, Brewer Jr HB. Renal HDL catabolism: Roles of cubilin and megalin receptors in Apo-AI catabolism in the canine cubilin dysfunctional animal model. *Circulation* 102:213, 2000.

- 32 Sloand EM, Kim S, Shamburek R, Brewer Jr. B, Moss J, Kirby M, Young NS. High density lipoproteins (HDL) may act as carriers for transfer of glycosylphosphatidylinositol (GPI)-linked proteins from blood cells to deficient cells in paroxysmal nocturnal hemoglobinuria (PNH). *Blood* 96:994, 2000.
- 33 Sarlis NJ, Summer A, Shamburek R. A case of familial dysbetalipoproteinemia (FDB) with very low serum high-density lipoprotein (HDL)-cholesterol: response to statin therapy. Abst 1807. *Endocrine Society* 82nd annual meeting. June 21-24, 2000.
- 34 Joyce C, Vaisman BL, Amar MJ, Lambert G, Fruchart-Najib J, Neufeld EB, Remaley AT, Shamburek RD, Brewer Jr. HB, Santamarina-Fojo S. Human ABCA1 transgenic mice: hepatic and macrophage expression of ABCA1 increases plasma HDL concentration and enhances biliary cholesterol excretion. *Circulation* 104:715, 2001.
- 35 Lambert G, Amar MJ, Shamburek RD, Cain WJ, Santamarina-Fojo S, Brewer HB. Sites of catabolism of apoA-I and apoA-II using Tyramine Cellobiose in control mice and mice with genetic dyslipoproteinemias. *Circulation* 104:1293, 2001.
- 36 Amar MJA, Lambert G, Joyce C, Shamburek RD, Fruchart-Najib J, Santamarina-Fojo S, Brewer Jr. HB. Kinetic analysis in ABCA1 transgenic mice reveals delayed HDL enhanced apoB-lipoprotein catabolism resulting in a protective lipoprotein profile and reduced atherosclerosis. *Circulation* 106:1258, 2002.
- 37 Chen JT, Csako G, Wesley R, Shamburek R, Pucino F. Meta-analysis of natural therapies for hyperlipidemia: policosanol vs. plant stanol esters. Spring Research Forum, The American College of Clinical Pharmacy. Palm Springs, Calif. April 27-30, 2003.
- 38 Genschel J, Tietge UJ, Shamburek R, Lochs H, Zech LA, Brewer Jr. HB, Hobbs H, Schmidt HH. Homozygosity for the Q136X mutation within the ARH gene results in delayed in vivo LDL catabolism. *Gastroenterology* 124: A59, 2003.
- 39 Wu JE, Basso F, Shamburek RD, Amar MJ, Vaisman B, Tansey T, Freeman L, Paigen B, Fruchart-Najib J, Brewer Jr. HB, Santamarina-Fojo S. Overexpression of human ABCG5 and ABCG8 in transgenic mice: effects on intestinal cholesterol absorption, biliary sterol excretion and atherosclerosis. P241. ATVB Annual Meeting, Washington D.C. May 8-10, 2003.
- 40 Shamburek RD, Nong R, Hoyt R, Brewer Jr. HB. Roles of cubilin and megalin in apolipoprotein A-I renal catabolism in the cubilin dysfunctional canine model. *Atherosclerosis* 4:235, 2003.

- 41 Shamburek RD, VandenBroek JM, Cooper PS, Brewer Jr. HB, Schwartz CC. Cholesteryl ester output to tissues directly from HDL is minimal in humans. *Circulation* 108:629, 2003.
- 42 Wu J, Basso F, Shamburek R, Amar M, Vaisman B, Tansey T, Freeman L, Szakacs G, Knapper K, Paigen B, Fruchart-Najib J, Brewer Jr. HB, Santamarina-Fojo S. Differential hepatic and intestinal overexpression of human ABCG5 and ABCG8 in transgenic mice: effects on intestinal cholesterol absorption, biliary sterol excretion and atherosclerosis. *Circulation* 108:1223, 2003.
43. Liu L, Joyce C, Vaisman B, Basso F, Amar MJA, Shamburek RD, Santamarina-Fojo S, Brewer Jr. HB. Contribution of Hepatic and Extrahepatic ABCA1 to Plasma HDL-C and ApoB-containing Lipoprotein Cholesterol in Transgenic Mice *Circulation* 112:897, 2005.
44. Hawari FI, Shamburek RD, Adamik B, Kaler M, Levine SJ. Identification and characterization of TNFR1 exosome-like vesicles in human plasma. *FASEB* 2006. Feb 11-14, 2006. Long Beach, CA.
45. Baker EH, McKeon JL, Shamburek RD. Quantitative MR spectroscopy for monitoring of cerebrotendinous xanthomatosis. ISMRM, Seattle May, 2006.